地西他滨作为核心结合因子急性髓系白血病维持治疗的活性研究
这项前瞻性研究对31例新诊断核心结合因子急性髓系白血病(CBF-AML)患者,在FLAG方案诱导/巩固后给予地西他滨(DAC)维持治疗,并用qRTPCR和流式细胞术监测可测量残留病(MRD)。23例维持前qRTPCR≥0.01%的患者中12例(52%)达到完全分子学缓解(CMR),应答者中位分子无复发生存期93.9个月。
要点
- 31例CBF-AML患者接受DAC维持治疗,其中15例为FLAG巩固后MRD阳性,16例因高龄或并发症未完成巩固。
- 23例维持前qRTPCR≥0.01%的患者中,12例(52%)达到CMR,应答者中位分子RFS为93.9个月。
- 应答者至新治疗中位时间112.4个月 vs 非应答者5.8个月(HR=0.16,95%CI 0.04-0.54),但总生存无差异(p=.37)。
核心结论
- DAC是FLAG方案后持续低水平融合转录本的CBF-AML患者的有效维持治疗。
- 通过DAC维持达到CMR可使FLAG方案后持续MRD阳性或无法接受全疗程巩固的患者获得长期缓解。
研究设计与样本
- 前瞻性研究,纳入31例新诊断CBF-AML患者,包括14例t(8;21)和17例inv(16)。
- 患者在FLAG方案诱导/巩固后接受胃肠外DAC维持治疗,并用qRTPCR和流式细胞术监测骨髓MRD。
- qRTPCR阴性(CMR)定义为融合转录本<0.01%。
主要发现
- 15例(48.3%)完成FLAG方案诱导/巩固但MRD阳性(0.35%,范围0.01%-0.91%)(组1)。
- 16例(51.7%)因高龄或并发症未能完成推荐巩固而转为DAC维持(组2);其中8例(50%)MRD不可测(qRTPCR≤0.01%)(组2A),另8例(50%)qRTPCR有残留融合产物(0.1%,范围0.02%-0.36%)(组2B)。
- 23例维持前qRTPCR≥0.01%的患者(组1和组2B)中,12例(52%)达到CMR作为最佳缓解。
- 应答者DAC前中位qRTPCR为0.03%,非应答者为0.14%(p=.002)。
- 应答者中位估计分子RFS为93.9个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posttherapy measurable residual disease (MRD) positivity in core binding factor acute myeloid leukemia (CBF-AML) is associated with shorter relapse-free survival (RFS). Elimination of MRD measured via quantitative reverse transcription polymerase chain reaction (qRTPCR) for disease specific transcripts can potentially lead to better outcomes in CBF-AML. METHODS: We prospectively monitored the MRD using qRTPCR and flow cytometry on bone marrow samples in patients with newly diagnosed CBF-AML who received decitabine (DAC) maintenance therapy after fludarabine/cytarabine/G-CSF (FLAG)-based induction/consolidation regimen. Negative qRTPCR (CMR) was defined as fusion transcript <0.01%. RESULTS: Thirty-one patients with CBF-AML including 14 with t(8;21) and 17 with inv(16) received parenteral DAC as maintenance therapy. Fifteen patients (48.3%) had completed FLAG-based induction/consolidation but with positive MRD (0.35%, range = 0.01%-0.91%) (Group 1). Sixteen patients (51.7%) could not complete recommended consolidations with FLAG-based regimen (due to older age or complications) and were switched to DAC maintenance (Group 2). In Group 2, eight patients (50%) had undetectable MRD (Group 2A) (all had qRTPCR ≤ 0.01%) and the other eight patients (50%) had residual fusion product by qRTPCR (0.1%, range = 0.02%-0.36%) (Group 2B) prior to starting DAC. Amongst the 23 patients who had a PCR ≥ 0.01% before maintenance therapy (Groups 1 and 2B), 12 patients (52%) attained a CMR as their best response (responders). The median pre-DAC qRTPCR amongst responders were 0.03% compared to 0.14% in nonresponders (p = .002). The median estimated molecular RFS amongst responders were 93.9 months. At a median follow-up of 59.3 months (13.2-106 months) from DAC initiation, 16 patients (51.6%) had to be initiated on a second line of therapy (40%, 25%, and 100% patients, respectively, in Groups1, 2A, and 2B). The median estimated time to new treatment between responders was 112.4 versus 5.8 months in nonresponders (hazard ratio = 0.16, 95% confidence interval = 0.04-0.54); however, there were no difference in overall survival between these groups (p = .37). CONCLUSION: DAC is an effective maintenance therapy for CBF-AML patients with persistent fusion transcript at a low level after FLAG-based regimen. Attainment of CMR with DAC maintenance can lead to long-term remission in patients who have persistent MRD positive after FLAG-based regimen or are unable to receive the full course of consolidation therapy.
引用
- Senapati J, Shoukier M, Garcia-Manero G, et al. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022. PMID: 35150150. doi:10.1002/ajh.26496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。